INTRODUCTION
The development and life-time of multicellular eukaryotic organisms represents a complex interplay of numerous proliferation and differentiation events that proceed in a highly ordered manner. As a prerequisite for those events Figure 1 schematically summarizes the pathways of signal transduction (for review see Parker, 1991; Karin, 1992) . In view of the complex interplay of signal transduction components that regulate proliferation and differentiation events, it is not surprising that most if not all known proto-oncogenes have turned out to represent proteins involved in signal transduction pathways at all levels, i.e. ligands, receptors, transducers and effectors (for a review see Hunter, 1991) . Most of the components of signal transduction pathways are proteins whose activity is altered by either ligand or second messenger binding, by covalent modifications and by subsequent changes in conformation or subunit number. The majority of covalent modifications observed are phosphorylations on tyrosine or serine/threonine residues, and both Tyr-or Ser/Thrspecific kinases and their protein substrates are present amongst the numerous components of signal transduction. Moreover, some of these protein kinases are themselves substrates of other protein kinases or modulate their own activity by (multiple) autophosphorylation reactions.
Two prominent Ser/Thr-specific kinases, both activated by second messenger action, play a central role in signal transduction: the cyclic AMP-dependent protein kinase A (PKA) (for a review see Taylor et al., 1990) and the Ca2+/phospholipidactivated protein kinase C (PKC) (this Review). The latter emphasizes its role as a key enzyme in signal transduction by the fact that it represents the direct "receptor" protein of phorbol esters, substances known to interfere dramatically with proliferative and differentiation events by promoting oncogenic transformation of cells in vivo and in situ. (To avoid misunderstanding we define data from intact animals or tissue as in Extracellular ligands bind to their cellular receptors. Hydrophobic ligands such as steroid hormones diffuse through membranes and bind to intracellular receptors that directly activate transcription. Activated receptors consisting of a structure with seven transmembrane domains (7TM receptors) interact with a transducer which in turn stimulates an effector. Activated receptors with Tyr kinase activity can directly activate several effector systems. The activated effectors generate second messengers which activate a target cascade leading to gene expression. In many cases PKC is the first target. For a complete description of signal transduction see Parker (1991) , Hunter (1991) and Karin (1992 Parker et al., 1986a Coussens et al., 1986 Knopf et al., 1986 Ohno et al., 1987 Ono et al., 1988a Rose-John et al., 1988 Megidish and Mazurek, 1989 Finkenzeller et al., 1990 Ono et al., 1986 Kubo et al., 1987a Housey et al., 1987 Housey et al., 1988 Ohno et al., 1987 Coussens et al., 1986 Coussens et al., 1986 Knopf et al., 1986 Ono et al., 1986 Kubo et al., 1987a Ohno et al., 1987 Tang and Ashendel, 1990 Coussens et al., 1986 Coussens et al., 1986 Knopf et al., 1986 Ono et al., 1988a Ohno et al., 1988b Ono et al., 1988b Mizuno et al., 1991 Mischak et al., 1991a Ohno et al., 1988a Ono et al., Schaap et al., 1989 Ono et al., 1988b Ono et al., 1 989a Osada et al., 1990 Bacher et al., 1991 , 1992 Dekker et al., 1992 Osada et al., 1992 vivo, data from cell culture as in situ, and data obtained from experiments with cell-free components as in vitro.) The discovery that PKC represents a large gene family of isoenzymes differing remarkably in their structure and expression in different tissues, in their mode of activation and in substrate specificity may enable us to elucidate the key role of PKC isoenzymes in signal transduction and to link PKC isoenzyme action to the modulation of gene expression necessary for changes in the proliferative and differentiation status of eukaryotic cells.
In this Review, we have compiled current knowledge on the action of PKC isoenzymes with the goal of evaluating the possibility that signal transduction pathways lead to quite divergent responses by usage of the different PKC isoenzymes. Within this scope, we have refrained from citing numerous references that are compiled in detailed reviews on PKC which have appeared at regular intervals in the past Nishizuka, 1988; Kikkawa et al., 1989; Bell and Bums, 1991; Azzi et al., 1992; Clemens et al., 1992 (Takai et al., 1979) or phorbol esters and phospholipids (Castagna et al., 1982) . From biochemical studies and purifications (Huang et al., 1986a) , it soon became clear that PKC represented a group of at least three isoenzymes or isoforms (a, /3, y), but the major breakthrough emerged from cloning the cDNAs of an ever increasing number of PKC isoforms, mostly from brain cDNA libraries (see references in Table 1 ). So far, the cDNAs coding for nine different PKC isoenzymes have been cloned from different species and tissues or cell lines (Table 1 ; following the nomenclature of Nishizuka, 1988) . They can be divided into two main groups: the Ca2+-dependent or conventional PKCs (cPKCs) and the Ca2+-independent or novel PKCs (nPKCs) . The PKC isoforms a, A1, fIl and y belong to the Ca2+-dependent group, and the isoforms 8, e, C, y and 0 to the Ca2+-independent group. The recently identified murine (Osada et al., 1990) and rat (Dekker et al., 1992) PKC y is identical with the human PKC L (Bacher et al., 1991 (Bacher et al., , 1992 and we refer to these PKCs as PKC y (Table 1) . The PKC e'-cDNA (Ono et al., 1988b) is very likely to represent a partial e-cDNA clone since no e'-protein could be identified by overexpressing the human e'-cDNA in either mammalian or insect cells (H. Hug et al., unpublished work) . For a comparison of the mammalian PKC isoenzymes with those from lower eukaryotes, which would exceed the scope of this Review, the reader should refer to . The primary amino acid structure, deduced from the cDNA sequences available, can be divided into conserved and thus presumably functional domains (Cl-C4) which are separated by variable regions (V1-V5), the function of which is not yet evident (Coussens et al., 1986) . All PKC isoforms contain these constant and variable regions in a single subunit protein, although the nPKC isoenzymes differ in part from the structure of the cPKCs (Figure 2 ). The C-terminal regions C3-V5 have been defined in all PKC isoenzymes as the catalytic domain, which is separated by the V3 region from the N-terminal regulatory domain.
The N-terminal VI region of the cPKC isoenzymes is a short stretch of approximately 20 amino acids and no function has been attributed to this region. In contrast, the VI region of the nPKC isoenzymes is rather extended and may well influence or modulate the function of the conserved domains common to both c-and nPKC isoforms.
At the beginning of the C1 region, a sequence motif is located that is similar to the consensus sequence xRxxS/TxRx found in the phosphorylation sites of prominent PKC substrates Graffet al., 1989; Kemp and Pearson, 1990; House and Kemp, 1990) . However, the serine or threonine residue found in the substrate motif is changed to alanine in all PKC isoenzymes (Figure 3) . Thus, this motifcannot be phosphorylated and is very likely to represent a pseudosubstrate site that exhibits autoregulatory features (Soderling, 1990) by blocking the catalytic (substrate binding) site. In fact, pseudosubstrate peptides are rather efficient inhibitors of PKC both in vitro and in situ Eicholtz et al., 1990; Shen and Buck, 1990) ; likewise, synthetic peptides containing this sequence with alanine replaced by a serine residue can be used as in vitro substrates Schaap et al., 1989; Olivier and Parker, 1991; Dekker et al., 1992) . A PKC a mutant containing a glutamic acid residue at position 25 ( Figure 3) showed an increase in effector-independent kinase activity and in its sensitivity towards proteolytic activation (Pears et al., 1990) , and anti-pseudosubstrate antibodies could be used to activate PKC in vitro (Makowske and Rosen, 1989) . On the basis of the pseudosubstrate sequence, one can speculate on the substrate specificity of PKC isoenzymes; however, a comparison of these sites ( Figure 3 ) does not reveal any significant differences and nor do the cPKC isoenzymes a, fI and y show any distinct differences when probed with the respective substrate peptides . It should be noted, however, that within natural (holoprotein rather than peptide) substrates of PKC, structures of higher order may determine substrate specificity (Kemp and Pearson, 1990) .
The Cys-rich region within the Cl domain (Figures 2 and 3 ) consists of two zinc finger motifs each with six cysteine residues, a DNA-binding motif found in transcription factors like GAL4 (Pan and Coleman, 1990 Figure 3 Sequence motffs of PKC isoenzymes Sequences are taken from human PKC oc (Finkenzeller et al., 1990) , human PKC /1l/Il (Kubo et al., 1987) ; human PKC y (Coussens et al., 1986; H. Hug, unpublished work) , rat PKC 6 and e (Ono et al., 1988) , rat PKC C (Ono et al., 1989) , murine PKC y (Bacher et al., 1991 (Bacher et al., , 1992 ) and murine PKC 6 . Asterisks indicate conserved amino acids, arrowheads the calpain and 11 cleavage sites in PKC a, f and y or tryptic cleavage sites in murine PKC e . The murine PKC e sequences shown in the V3 region are identical with the respective rat sequence. Longer stretches of non-homologous amino acids within the conserved sequences are marked with X followed by the number of amino acids not depicted.
is detectable. For PKC isoenzymes no DNA-binding activity has been demonstrated, but the regulatory subunit alone, generated by proteolytic cleavage in the V3 hinge region (see below), may bind. Three further proteins, diacylglycerol (DAG) kinase (Sakane et al., 1990; , c-Rafkinase isoenzymes (Bruder et al., 1992) and n-chimaerin (Ahmed et al., 1990) , show no DNA-binding activity although they contain a zinc finger motif The use of deletion mutants of different PKC isoenzymes revealed that the Cys-rich region is necessary for DAG and phorbol ester binding (Muramatsu et al., 1989; Kaibuchi et al., 1989; Burns and Bell, 1991) . Moreover, the Cl domain, expressed in Escherichia coli, exhibited phospholipid-dependent phorbol ester binding (Ono et al., 1989b) . PKC C contains only one zinc finger ( Figure 3 ) and does not bind DAG or phorbol ester (Ono et al., 1989a; McGlynn et al., 1992) ; this is in agreement with the finding that, at least in vitro, PKC 4 exhibits a constitutive protein kinase activity McGlynn et al., 1992; Nakanishi and Exton, 1992) which might be influenced in vivo by other unknown factors. It seems noteworthy that all PKC isoenzymes, even PKC 4 exhibit a distinct distance of 15 amino acids from the end of the pseudosubstrate box to the beginning of the zinc finger motif (see Figure 3) . The Ca2l-independent nPKCs lack the C2 region ( Figure 3 ), which is thought to represent the Ca2+-binding domain of the cPKCs (Ono et al., 1988b; Ohno et al., 1988a) . No sequence motif that represents a known Ca2+-binding site, e.g. the classical E-F hand binding motif, could be identified, but the C2 region contains many acidic amino acids which are thought to participate in Ca2+ binding (Ohno et al., 1987) . Nevertheless, homologies of the C2 domain of the cPKCs with sequences of other Ca2+-binding proteins have been reported, e.g. with phospholipase A2 (Clark et al., 1991) , phospholipase C-y (Stahl et al., 1988) and two synaptic vesicle Ca2+-dependent proteins (Penn et al., 1990; Geppert et al., 1991) .
The V3 or hinge region separates the regulatory from the catalytic domain (Figure 2 ). This region is sensitive to proteolytic cleavage by trypsin or the Ca2+-dependent neutral proteases calpain I and II which leads to a constitutively active kinase (Kishimoto et al., 1983; Huang and Huang, 1986; . PKC a is more resistant to proteolytic digestion than PKC ft and y (Huang et al., 1989; Kishimoto et al., 1989; Kochs et al., 1993) . The cleavage sites for PKC a, f and y by calpain I and II and for PKC e by trypsin have been determined and are depicted in Figure 3 , though no obvious consensus sequence can be found between those and other nPKC isoenzymes. Further experimental evidence will be necessary to determine whether or not the V3 region of the different PKC isoenzymes exhibits certain features that modulate the susceptibility to proteolytic cleavage. Recent findings (James and Olson, 1992) (Taylor et al., 1990; Kemp and Pearson, 1990 McGlynn et al., 1992; Kochs and H. Hug, unpublished work) .
The C4 region contains the substrate binding site and the phosphate transfer region (Figure 3 ). The central element in the phosphate transfer region, again highly conserved amongst protein kinases (Taylor et al., 1990; Kemp and Pearson 1990) , is the sequence DFG. The Asp residue is thought to be responsible for the transfer of the phosphate group to substrates. In all PKC isoenzymes, there is a conserved distance of 105-108 (113 in PKC y) amino acids between the end of the ATP-binding site and the beginning of the phosphate transfer region. Again, PKC C exhibits a slight deviation from the consensus sequence DFG with a substitution of phenylalanine by tyrosine.
THE BIOCHEMICAL PROPERTIES OF PKC ISOENZYMES
Though certain features of the PKC isoenzymes can be deduced from the protein structure derived from the sequence of the cloned PKC cDNAs (see above), the greater body of information has been accumulated by detailed biochemical analyses. Those studies were carried out with isoenzymes purified to homogeneity mostly from rat, rabbit or bovine brain (Huang et al., 1986a; Jaken and Kiley, 1987; Sekiguchi et al., 1988; Marais and Parker, 1989; Leibersperger et al., 1990; Koide et al., 1992; Ogita et al., 1992; Saido et al., 1992) . To date, expression of isoenzyme cDNAs in either COS cells or recombinant baculovirus-infected insect cells allows for the purification of distinct PKC isoenzymes for biochemical characterization (Knopf et al., 1986; Ohno et al., 1988a; Ono et al., 1989a; Patel and Stabel, 1989; Burns et al., 1990; Fiebich et al., 1990; Akita et al., 1990; Osada et al., 1990; Olivier and Parker, 1991; Burns and Bell, 1991; Liyanage et al., 1992; McGlynn et al., 1992; Osada et al., 1992; Dekker et al., 1992) . The molecular mass values of these PKC isoenzymes, either calculated from the open reading frame of the respective cDNA sequence or reported from SDS/PAGE analyses, are listed in Table 2 . The obvious deviations of these values are thought to be due to co-or post-translational modifications (see below); in several cases, a doublet of protein bands is observed.
Efficient in vitro assays have been developed to study partially or highly purified fractions of PKC isoenzymes derived from the sources mentioned above. As a major advance, the use of DAG/PtdSer vesicles (generated by sonication) as the classical activator of PKC (Takai et al., 1979; Castagna et al., 1982) has been substituted by so-called mixed micelles as the activating principle of PKC (Hannun et al., 1985) . The latter, composed of (phospho)lipid activator(s) embedded in Triton X-100 micelles, have proven to virtually mimic the situation of the cellular membrane environment of PKC and has minimized artifacts such as damage to vesicle structure by the presence of Ca2+ . Originally, histones (HI or III-S), myelin basic protein (MBP) or protamine were used as substrates for PKC isoenzymes (Jakes et al., 1988; Burns et al., 1990) , but synthetic peptides derived from the Ala -+ Ser mutated pseudosubstrate sequence Schaap et al., 1989; Olivier and Parker, 1991; Dekker et al., 1992) or from known PKC substrates, e.g. the EGF receptor or MBP Yasuda et al., 1990 ) have proven to be adequate and even more specific substrates. This has been supported by the recent finding kinase activity on histone, MBP or protamine Dekker et al., 1992) .
By means of those in vitro systems, the biochemical properties of the different PKC isoenzymes have been investigated with respect to the activation, autophosphorylation, proteolytic activation/degradation and, last but not least, substrate specificity.
Activation
The finding that PKC represents a (phospho)lipid dependent protein kinase has drawn attention to the cellular glycerolipids, sphingolipids and their metabolic breakdown products (Berridge 1987 (Berridge , 1989 and the enzymes involved in lipid metabolism, i.e phospholipases and Ptdlns kinase(s) (Meldrum et al., 1991) . At least for the cPKCs, a model of activation was sufficient and convincing that included (i) the generation of DAG and Ins(1,4,5)P3 from plasma membrane-associated Ptdlns(4,5)P2 by the action of phospholipase C, (ii) the release of Ca2+ from intracellular storage sites stimulated by Ins(1,4,5)P3, (iii) the binding of Ca2+ to the C2 region of PKC and subsequent translocation of the enzyme to the plasma membrane, (iv) where it is activated, via its Cl region, by DAG and PtdSer, the latter being constitutively present in the membrane (reviewed by Bell and Burns, 1991; Gschwendt et al., 1991; Zidovetzki and Lester, 1992) . In this model, phorbol ester would mimic the action of DAG and, by its persistence in the cellular membrane, lead to a long-term activation of PKC  and references cited therein).
Activation of the cPKCs is thought to require DAG as activator and PtdSer as cofactor of activation, the presence of both reducing the Ca2+ requirement of PKC to the micromolar range (Lee and Bell, 1991 , and references cited therein). For activation with phorbol esters in the case of cPKCs, the presence of Ca2+ is not required but lowers the concentration of phorbol ester necessary to obtain full PKC activity (Ryves et al., 1991) . As outlined above, members of the nPKC group do not require Ca2+ for activation, but require either DAG/PtdSer or PMA/PtdSer, except for PKC C which exhibits a low but constitutive activator-independent kinase activity McGlynn et al., 1992) . However, Nakanishi and Exton (1992) have reported a marked stimulation of PKC ( activity (purified from bovine kidney) by PtdSer or unsaturated fatty acids, e.g. arachidonic acid.
Recently it has been shown that other components of glycerolipid metabolism can be activators of PKC, at least in vitro (Lee and Bell, 1991; Chauhan et al., 1991; Orr and Newton, 1992; Kochs et al., 1993) . Cardiolipin is able to activate PKC a, /3I (Kochs et al., 1993 ) and e . Arachidonic acid (Kikkawa et al., 1989; Burns et al., 1990; Ogita et al., 1992) and even better lipoxin A (Shearman et al., 1989) , another lipoxygenase metabolite, are capable of activating PKC ,/11, y (Shearman et al., 1989 ) and e , even in a Ca2-independent fashion. PKC a can be activated by arachidonic acid only in the presence of Ca2 , whilst PKC /3I and a do not respond at all (Shearman et al., 1989; Burns et al., 1990) . Surprisingly, Ptdlns(4,5)P2 can substitute for DAG (Chauhan et al., 1991) as an activator of PKC a, /3I and y (Lee and Bell 1991; Kochs et al., 1993) , but not of /311 (Lee and Bell, 1992) , and Ptdlns can replace PtdSer as cofactor of activation, at least for PKC a and /31 (Kochs et al., 1993) . These findings, together with observations that DAG can be generated in an inositol lipidindependent way, e.g. from phosphatidylcholine (Huang and Cabot, 1990; Cataldi et al., 1990) Parker et al., 1986; Marais and Parker, 1989; Burns et al., 1990; Borner et al., 1992 Ono et al., 1987 Coussens et al., 1986 , Ono et al., 1987 , Burns et al., 1990 Coussens et al., 1986 Patel and Stabel, 1989 , Burns et al., 1990 Ono et al., 1988b McGlynn et al., 1992; Olivier and Parker, 1991; Ogita et al., 1992; Borner et al., 1992; Liyanage et al., 1992 Ohno et al., 1988a Borner et al., 1992; Liyanage et al., 1992; Koide et al., 1992; Saido et al., 1992 Ono et al., 1989a Nakanishi and Exton, 1992; McGlynn et al., 1992; Liyanage et al., 1992 Osada et al., 1992 Dekker et al., 1992; Greif et al., 1992 Osada et al., 1992 messengers in a distinct way. Cytokines such as IFN-a, IL-I and IL-3 have been reported to induce phosphatidylcholine hydrolysis, but not inositol phospholipid turnover (Duronio et al., 1989; Cataldi et al., 1990; Pfeffer et al., 1990) , and recently, selective activation of PKC and e by IFN-a treatment of HeLa and Daudi cells, respectively, has been demonstrated (Pfeffer et al., 1990 (Pfeffer et al., , 1991 . Thus, the signal-induced production of a distinct second messenger or activator may actually decide which PKC isoenzyme becomes activated or not. Moreover, a detailed study on the activation potency of different phorbol ester derivatives on PKC isoenzymes reveals quite distinct differences, e.g. for PKC 8 and PKC ,8I (Ryves et al., 1991) . Autophosphorylation Most protein kinases described so far exhibit a rather pronounced autophosphorylation which is often but not necessarily linked to a modulation of kinase activity (Miller and Kennedy, 1986; Galabru and Hovanessian, 1987) . Autophosphorylation has also been reported for all PKC isoenzymes known, e.g. PKC a (Pears et al., 1992) , (Kochs et al., 1993) , 31E1 (Flint et al., 1990) , y (Patel and Stabel, 1989; Fiebich et al., 1990) , a , e Saido et al., 1992) , e (R. Hummel and G. Kochs, personal communication), (Osada et al., 1990; Dekker et al., 1992) and 0 . Detailed studies on the role of autophosphorylation have mostly been carried out with cPKC isoenzymes and have revealed that it is an intramolecular reaction at serine and threonine residues on both the regulatory and catalytic domains (Huang et al., 1986b; Mochly-Rosen and Koshland, 1987; Newton and Koshland, 1987) . As expected, autophosphorylation has a Km value for ATP about 10-fold lower than that for substrate phosphorylation and is strictly dependent on the presence of activators (Huang et al., 1986b; Newton and Koshland, 1989) . Though it has been reported to affect PMA and Ca2l binding (Huang et al., 1986b) and the Km value for histone HI as substrate (Mochly-Rosen and Koshland, 1987) , autophosphorylation clearly seems not to be a prerequisite for PKC activity, but rather a concomitant event. A detailed study on PKC /311 (Flint et al., 1990) nevertheless revealed certain interesting features of autophosphorylation: (i) all phosphorylated residues were found in variable regions of PKC (see Figures 2 and 3) , i.e. VI (Ser-16, Thr-17) right before the Cl box, V3 (Thr-314, Thr-324) and V5 (Thr-634, Thr-641); (ii) the surrounding amino acid context did not exhibit any consensus sequence nor any similarity to the pseudosubstrate/ substrate consensus motif (see above), though some selectivity must exist since threonine and serine residues next to autophosphorylated ones (e.g. Thr-314 and Thr-324) are not phosphorylated ( Figure 3) ; (iii) the distribution of autophosphorylation sites over the N-terminus, the hinge region and the C-terminus indicates a close proximity of these regions to the catalytic centre of PKC, in spite of the fact that the current model of activator binding (a prerequisite of autophosphorylation) postulates a complete or partial unfolding of the PKC molecule Zidovetzki and Lester, 1992) . Whilst PKC /3ll phosphorylates on both serine and threonine residues (Flint et al., 1990 ), a comparative phospho-amino acid analysis of highly purified PKC a, /3I and S revealed almost exclusive autophosphorylation of PKC a and C on serine; in contrast, PKC /11 autophosphorylates primarily on threonine residues (S. Gaubatz and T. Sarre, unpublished work).
Reports on a potential role of autophosphorylation for the proteolytic activation and degradation of PKC (see below) have been controversial: whilst Ohno et al. (1990) found a severe impairment of PMA-induced downregulation for a kinasenegative mutant of PKC a expressed in COS cells or rat fibroblasts, kinase-negative mutants of PKC a and y expressed in COS cells could be downregulated by PMA Freisewinkel et al., 1991) . Moreover, inhibition of endogenous PKC activity by the potent inhibitor K252a did not prevent downregulation in Swiss 3T3 cells (Lindner et al., 1991) . Nevertheless, autophosphorylation, as one of the immediate early events of PKC activity, may be used as a potential measure of activation (Mitchell et al., 1989; Molina and Ashendel, 1991; Pfeffer et al., 1991; Gaubatz and T. Sarre, unpublished work) and may reveal isoenzyme-specific activation in distinct signalling pathways.
Several reports suggest a post-or even co-translational phosphorylation of PKC prior to activation (Borner et al., 1989; Pears et al., 1992) . Without this initial phosphorylation, PKC is Protein kinase C isoenzymes 335 inactive and cannot be activated. This observation is supported by the finding that PKC expressed in E. coli is inactive (Dietrich et al., 1989) due to the lack of an as yet unidentified PKC kinase present only in eukaryotic cells. In this respect, protein phosphatases become relevant (Parker et al., 1986b) , and it is notable that, at least with PKC a, potato acid phosphatase is capable of dephosphorylating PKC without loss of PKC activity, whilst protein phosphatases 1 and 2A completely abolish PKC activity (Pears et al., 1992) . If autophosphorylation plays a role at all (if not for activity or proteolytic degradation then perhaps for translocation or substrate specificity), the localization of its target residues within the variable regions might indicate a role that is quite diverse between PKC isoenzymes.
Proteolytic activation and degradation
As mentioned above, PKC was first discovered as a proteaseactivated protein kinase (Inoue et al., 1977) , and only later did it become evident that proteolytic cleavage actually followed activation (Kishimoto et al., 1983) . The respective proteases in vivo are thought to be Ca2+-dependent neutral proteases I and II (calpains) which are active in the micromolar and millimolar concentration range of Ca2+ respectively (Inoue et al., 1977; Kishimoto et al., 1983) . Calpains cleave PKC in the V3 hinge region ( Figure 3 ) and thus produce two distinct fragments, a protein comprising the regulatory domain and a protein containing the kinase domain which is catalytically active in the absence of any activators Saido et al., 1992) . In vitro, this proteolytic activation can be achieved by a limited trypsin treatment (Huang et al., 1989; Newton and Koshland, 1989; Kochs et al., 1993) , though in vivo, activation of PKC and translocation to the cell membrane is thought to be a prerequisite for proteolytic cleavage. However, it is not yet clear whether further proteolytic degradation serves as a means of preventing continuing kinase activity or if the catalytic fragment, released from the membrane to the cytosol (and possibly to other cellular compartments), is capable of acting as a constitutive, activator-independent kinase. The latter possibility has found support in the recent observation that a PKC a mutant, devoid of the regulatory domain and expressed in COS cells, was selectively translocated to the nuclear envelope (James and Olson 1992) . Moreover, one could speculate that the regulatory fragment may now bind -by its zinc finger domainsto DNA (Murray et al., 1987 , and references cited therein). In many cell types, prolonged treatment with phorbol esters results in (almost) complete depletion of cellular PKC (so-called downregulation) which is in favour of the first alternative, i.e. prevention of permanent kinase activity. In other cases, cellular responses involving PKC could be blocked by the protease inhibitor leupeptin, thus indicating a distinct role of proteolytic cleavage (Pontremoli et al., 1990 , and references cited therein). With respect to downregulation, PKC isoenzymes exhibit quite extreme differences in vivo (see below) which is in agreement with observations in vitro. Compared to PKC , and y, PKC a is relatively resistant to both calpain-and trypsin-mediated proteolysis Huang et al., 1989; Kochs et al., 1993) . Moreover, tryptic activation of PKC e not only rendered the enzyme lipid-and PMA-independent but increased its kinase activity towards histone about 10-fold . Further work will be necessary to determine the role of proteolytic cleavage with respect to activation, degradation and relocalization to cellular compartments, and substrate specificity of PKC isoenzymes. It should be noted that recent reports isoenzymes during the process of cellular differentiation. A decrease of PKC e seems to accompany (or promote?) the differentiation of mouse erythroleukaemia cells (Melloni et al., 1989; Powell et al., 1992) , and the differentiation of a neuroblastoma cell line is promoted by an inactivation of PKC a and e (Leli et al., 1992 Kemp and Pearson, 1990) . Nevertheless, a comparison of PKC isoenzymes and their activities towards distinct substrates in vitro has revealed differences that may indicate an even more pronounced specificity towards natural substrates under physiological conditions. Kinase activities of PKC a, flI, and y towards histone IIIS, protamine or MBP are very similar Burns et al., 1990) , though PKC y has a 2-3-fold lower activity towards protamine or the pseudosubstrate site-derived synthetic peptide of PKC a or ft . Members of the nPKC group differ significantly from cPKC isoenzymes in that they exhibit a rather poor kinase activity (d > I > ) towards histone IIIS, MBP, protamine or protamine sulphate (Ono et al., 1989a; Olivier and Parker, 1991; Saido et al., 1992; Liyanage et al., 1992; McGlynn et al., 1992; Dekker et al., 1992) . Thus, it was sometimes necessary to use synthetic peptides derived from the respective pseudosubstrate sequence, the EGF receptor or MBP, to detect kinase activity of nPKC isoenzymes at all (Schaap et al., 1989; Saido et al., 1992; Ogita et al., 1992) . This may well explain the difficulties in detecting new PKC isoenzymes by biochemical analysis, if the appropriate substrates are not available.
Several observations indicate that substrate specificity may be more complex than expected. For PKC e, it could be demonstrated that proteolytic activation (see above) significantly increased its kinase activity towards histone indicating a distinct influence of the regulatory domain. Indeed, genetically engineered fusion of the PKC e regulatory domain to the PKC y catalytic domain imposed PKC e substrate specificity onto the chimaeric enzyme . A similar observation has been made with PKC C: chymotrypsin-mediated proteolysis results in a catalytic fragment which -in contrast to the intact isoenzyme -now accepts the EGF receptor peptide as substrate (R.Hummel and T. Sarre, unpublished work). In some cases, the activator requirement seems to depend on the substrate used; for phosphorylation of protamine or protamine sulphate, neither cPKC nor nPKC isoenzymes require any activator (Bazzi and Nelsestuen, 1987; Liyanage et al., 1992) . In order to phosphorylate an MBP-derived substrate peptide, but not the e-specific pseudosubstrate site-derived peptide, PKC e seems to require the presence of Ca2+ (Meek and Street, 1992) . It should be noted that amongst PKC substrates there might be several other protein kinases like S6 kinase or Raf kinase (see below).
Three prominent substrates, most likely involved in the control of cell proliferation mediated by PKC, should be mentioned, although little is known of the specificity of PKC isoenzymes towards them. The myristoylated, alanine-rich C kinase substrate (MARCKS) is phosphorylated by PKC under several conditions such as macrophage activation or growth-factor-dependent mitogenesis; its phosphorylation leads to a redistribution from the actin filaments of the membrane to the cytoplasm (Hartwig et al., 1992 , and references cited therein). Two further PKC substrates, DNA topoisomerase I (Pommier et al., 1990 ) and lamin B (Hornbeck et al., 1988; Fields et al., 1988) , are nuclear proteins and thought to be involved in the control of DNA synthesis; they gain interest in discussing a translocation of activated PKC isoenzymes to the cell nucleus (see below).
EXPRESSION OF PKC ISOENZYMES
The tissue distribution of the PKC isoenzymes has been determined mostly by Northern blot analyses and, more recently, by Western blotting using isoenzyme-specific antibodies. PKC a /3I/H1, 8, e and C seem to be ubiquitously distributed, e.g. in brain, lung, spleen, thymus and skin (Nishizuka, 1988; Wada et al., 1989; Yoshida et al., 1989; Schaap et al., 1989; Ohno et al., 1991; Wetsel et al., 1992) , whilst PKC y is exclusively found in the central nervous system, e.g. brain (Nishizuka, 1988; Wetsel et al., 1992) , and PKC y is strongly expressed in skin and lung and only slightly in brain and spleen (Osada et al., 1990; Bacher et al., 1991) . PKC 6 is predominantly expressed in skeletal muscle and, to a clearly lower extent, in lung, spleen, skin and brain . Two remarkable deviations from the distribution of the ubiquitous isoenzymes should be mentioned: PKC a and e seem not to be present in liver (Schaap et al., 1989; Rogue et al., 1990) , where PKC / is the major isoenzyme (Rogue et al., 1990) ; in contrast, no PKC / could be detected in kidney, i.e. renal mesangial cells, though PKC a, 8, e and e are present (Huwiler et al., 1992; see Table 3 ). Though it is still an open question why all PKC isoenzymes known so far are expressed in brain tissue, the remarkable differences in number and amount of PKC isoenzymes in other tissues make a concept of mere redundancy with respect to signal transduction rather unlikely. On the other hand, one or the other member of the ubiquitously distributed isoenzymes, e.g. PKC a or A1/11, may substitute for each other in different tissues with respect to identical or similar function. There nmay be even a distinction between isoenzymes for 'house-keeping' functions and those for distinct function in a differentiated, specialized cell, e.g. for PKC 6 in skeletal muscle .
In Table 3 , PKC isoenzyme expression patterns of (selected) cell lines from various origins have been accumulated, mostly determined by Northern or Western blot techniques..-In accordance with the tissue distribution described above, PKC ac, A1/II, 8, e and C seem to be the most ubiquitous isoenzymes, whilst PKC y is restricted to a neuronal cell line (PC12). Information on PKC I and 0 is as yet too limited. Though both PKC a and / are present in most cell lines investigated, in none system, however, PKC a is absent from myeloid cells of different origin (Mischak et al., 1991b) , megakaryocytes (HEL) and macrophages (Grabarek et al., 1992; Duyster et al., 1992) (Mischak et al., 1991b) . Since a true picture of PKC isoenzyme expression in different tissues and cell lines is rapidly emerging, it can be anticipated that the role of a given PKC isoenzyme in a distinct signalling pathway may become evident once it is possible to define a given cell type unequivocally by its PKC isoenzyme expression pattern and by its signal response potential.
Little is known about how the expression of PKC isoenzymes is regulated, due to the fact that information on the gene and promoter structure is (yet) limited. So far, the promoters of the rat PKC y (Chen et al., 1990) (Niino et al., 1992 , Obeid et al., 1992 . By deletion analysis, three positive and two negative regulatory regions could be identified in the 1.9 kbp region upstream from the transcription start site of the PKC promoter. Transcription under the control of these regions seems to be cell type specific (Niino et al., 1992 The PKC /31 and /311 isoforms differ in their 3-ends and originate by differential splicing. Genomic clones of the 3-end of the PKC gene have been isolated (Ono et al., 1987; Kubo et al., 1987b; Coussens et al., 1987) . According to the nomenclature of Kubo et al. (1987b) the /I-specific exon lies behind the ,fil-specific exon and is separated by an intron of 4-5 kbp (Kubo et al., 1987b; Coussens et al., 1987) . If PKC /8 is expressed at all in a given tissue or cell line (Table 3) , one splice form seems to be preferred, which indicates that the main regulation seems to occur at the level of alternative splicing. Differential splicing is also proposed for the PKC e locus . Following the activation model outlined above, translocation to (the) cellular membrane(s) has been regarded as an equivalent of the activation of the respective PKC isoenzyme. However, in various cell types, rather significant portions of certain PKC isoenzymes are constitutively present in the particulate fraction, and it is hard to believe that this indicates a permanent and persistent activation or activity as has been proposed (Bazzi and Nelsestuen, 1988; Burgoyne, 1989) . With cPKC isoenzymes, an increase in intracellular Ca2+ concentrations is thought to promote translocation to the cellular membrane where subsequent activation by DAG/PtdSer occurs. Following this line of thought, phorbol esters should not only be persistent activators of PKC within the cellular membrane, but should also exert a pleiotropic effect that leads to translocation of the respective isoenzymes. Moreover, phorbol ester treatment leads to the translocation of the Ca2+-independent nPKC isoenzymes, too, a mechanism which is not understood at all. Recent observations that phosphoinositides as such are capable of activating PKC in vitro (Chauhan et al., 1991; Lee and Bell, 1991; Kochs et al., 1993) allow for the possibility that translocation alone, without the additional production of second messengers and activators, may lead to the activation of the respective PKC isoenzyme.
In most cell lines investigated, e.g. those depicted in Table 3 , PKC a seems to be located in the cytosol and is translocated to the cellular membrane and downregulated upon PMA treatment (Hocevar and Fields, 1991; Strulovici et al., 1991; Huwiler et al., 1991; Crabos et al., 1991; Borner et al., 1992) . With more specific stimuli, however, remarkable differences are observed. In GH4C1 pituitary gland cells, PKC a is translocated to the particulate fraction, but not downregulated upon treatment with thyrotropin-releasing hormone (TRH) or PMA Kiley et al., 1990) . Likewise, the PKC a content of neuronal PC12 cells is unchanged over a 10 day period in the presence of nerve growth factor (NGF) (Wooten et al., 1992) . In NIH 3T3 cells, PKC a is reported to translocate to the nucleus upon PMA treatment (Leach et al., 1989) , and in Swiss 3T3 cells, PKC (presumably PKC a as the major isoenzyme in fibroblasts) seems to associate with the nuclear fraction upon treatment with insulin-like growth factor I, but with the cellular membrane in the presence of bombesin (Divecha et al., 1991) . As reported recently (James and Olson, 1992) , a PKC a mutant lacking the regulatory domain was associated primarily with the nuclear envelope.
PKC , also appears to be a cytosolic isoenzyme in unstimulated cells which is sensitive to downregulation by PMA (Huang et al., 1989; Akita et al., 1990; Kiley et al., 1990; Strulovici et al., 1991; Crabos et al., 1991; Cook et al., 1992; Duyster et al., 1992 Kiley et al., 1990) . Stimulation of human platelets with leads to a rapid translocation of PKC , that is more pronounced than that observed with PKC a (Cook et al., 1992) , and IFN-a induces a selective translocation of PKC , to the particulate fraction in HeLa cells (Pfeffer et al., 1990) . In HL 60 cells treated with retinoic acid (Makowske et al., 1988; Hashimoto et al., 1990) and in PC12 cells under long term treatment with NGF (Wooten et al., 1992) , PKC fll1 is significantly accumulated whilst the other isoenzymes are downregulated or unchanged. Recently, Tanaka et al. (1992) reported an increase in the activities of PKC a and ,3 during the differentiation of HL 60 cells and the appearance of a 'new' PKC isoenzyme when cells were induced to differentiation by retinoic acid. In rat liver and in HL 60 cells, a distinct portion of PKC , is reported to be found in the nuclear fraction (Kiss et al., 1988; Rogue et al., 1990; Hocevar and Fields, 1991) .
Depending on the cell type, PKC a seems to be differentially distributed within the cell. Whilst located in the cytosol in human platelets (Grabarek et al., 1992) , the majority of PKC a is found associated with the particulate fraction in rat6 fibroblasts (Borner et al., 1992) and in renal mesangial cells (Huwiler et al., 1992) . In the latter cell lines, the isoenzyme can be completely downregulated by PMA treatment (Borner et al., 1992; Huwiler et al., 1992) .
Rather controversial observations have been made with PKC c, which is mostly cytosolic in GH4C1 pituitary gland cells Kiley et al., 1990 ) and human neuroblastoma cells (A. Javala and K. Akerman, personal communication), but membrane-associated to a certain extent in U937 cells (Ways et al., 1992b) , rat6 fibroblasts (Borner et al., 1992) and renal mesangial cells (Huwiler et al., 1991) . In the latter cell lines, downregulation by PMA is significantly diminished (Huwiler et al., 1991; Borner et al., 1992) , whilst in the promonocytic cell line U937 as well as in thymocytes, PKC e is resistant to downregulation by prolonged PMA treatment . In contrast to PKC a and /3ll, PKC e is downregulated in GH4C1
pituitary gland cells by both PMA and TRH treatment Kiley et al., 1990) . IFN-a. treatment of Daudi cells has been reported to result in a selective and rapid activation of PKC e (Pfeffer et al., 1991) . In several cell lines investigated so far, PKC C seems to be present as a cytosolic isoenzyme (Crabos et al., 1991; Borner et al., 1992; Huwiler et al., 1992) ; only in HL 60 cells, has it been reported to be mostly in the particulate fraction (Ways et al., 1992a) . Again, translocation and downregulation by PMA appears to be dependent on the cell type. Whilst it is sensitive to PMA treatment in rat6 fibroblasts (Borner et al., 1992) and human platelets (Crabos et al., 1991) , it is resistant in HL 60 (Ways et al., 1992a) and renal mesangial cells (Huwiler et al., 1992) and in two neuronal cell lines (Wada et al., 1989; Wooten et al., 1992) . Sensitivity towards PMA treatment seems quite contradictory to the fact that PKC ( neither binds to nor can be activated by phorbol esters (Ono et al., 1989a; Liyanage et al., 1992; McGlynn et al., 1992) . However, especially for the nPKC isoenzymes, mechanisms of activation and degradation must be postulated which might involve other cellular (maybe cell typespecific) components; in fact, membrane-associated PKC-binding proteins have been reported which may serve to anchor or compartmentalize PKC isoenzymes to different intracellular membranes (Wolf and Baggiolini, 1990; Mochly-Rosen et al., 1991) .
In several human tumour cell lines, PKC y has been reported to be present specifically in the cell nucleus; PMA treatment does expressed in COS cells, the majority of the protein was found in the particulate fraction .
Concerning the data accumulated above, we have to admit to being far away from a clear-cut picture of the distribution, translocation and degradation ofPKC isoenzymes within distinct signalling pathways in different cells. Likewise, the concept of a "cell depleted of PKC by prolonged PMA treatment" has to be re-evaluated in the light of significant differences in PMA sensitivity between the PKC isoenzymes in various cells. However, a connection of the above findings with data on PKCmediated proliferation and differentiation events may bring us closer to detailed insights.
In order to investigate the role of distinct PKC isoenzymes as such and, especially, in the control of cell proliferation, PKC isoenzyme cDNAs have been stably overexpressed in several mammalian cell systems under the control of various promoters.
In general, the effects observed depend very much on the cell lines and the PKC isoenzyme cDNAs used.
Bovine PKC ax has been overexpressed in Swiss 3T3 cells (Eldar et al., 1990) and murine PKC a in BALB/c-, rat6-and Vf2-fibroblasts (Borner et al., 1991) . In all cases, no transformation could be observed by growing the cells in soft agar. Overexpression of human PKC a in NIH 3T3 fibroblasts resulted in a slightly transformed phenotype (Finkenzeller et al., 1992) which might be due to the parental cell line used. Overexpression of rat PKC /31 in rat6 fibroblasts gave rise to transformation, especially in the presence of PMA (Housey et al., 1988) , and phospholipase D activity and DAG formation were increased (Pai et al., 1991) . In contrast, overexpression of PKC ,/1 in rat liver epithelial cells was not sufficient by itself for cell transformation (Hsieh et al., 1989) . No alterations were observed by overexpressing rat PKC /31 in C3H 10TI/2 cells (Krauss et al., 1989) , whereas PMA exerted even an inhibitory effect on cell proliferation in HT29 colon cancer cells overexpressing the same PKC isoenzyme (Choi et al., 1990) .
Rat PKC y overexpression in NIH 3T3 fibroblasts may (Persons et al., 1988) or may not (Cuadrado et al., 1990) (Persons et al., 1991) .
Overexpression of the murine PKC a in NIH 3T3 cells gave rise to a slower cell growth rate, whereas overexpression of murine PKC e in the same cell line led to an increased growth rate (H. Mischak, personal communication fibroblasts, it was possible to overexpress PKC ,/1 (Housey et al., 1988 ) and a (Borner et al., 1991) 40-50-fold at the protein level, whereas the maximal expression level in other cell lines was up to 10-fold, so far. The PKC ,8I-overexpressing rat6 cell line (Housey et al., 1988) T cells Activation of T cells by antigens, anti-receptor antibodies, IL-1, lectins, PMA, or a combination of these, leads to the expression of IL-2 and the 55 kDa a-subunit of the IL-2 receptor (IL-2Ra) which results in an autocrine stimulation of proliferation (reviewed by . In this classical model system, PKC is undoubtedly involved in the activation process, and although a rapid translocation of PKC has been observed, it is clear that PKC activation is required for a prolonged length of time . In this context, the observation that PKC /3, but not PKC e, is downregulated during thymocyte activation by PMA might gain some significance.
During T cell activation, the expression of the c-fos, but not the c-jun,.gene product is enhanced; these two proteins, as homoor heterodimeric complexes, represent the transcription factor API which confers inducibility by PMA to genes containing a TRE (TPA-response element) within their promoter DNA sequence (for details see Karin, 1992) . Activation of the DNA-binding activity of APl seems to involve both PKC-mediated phosphorylation of c-Fos and dephosphorylation of c-Jun (reviewed by Karin 1992; Meek and Street 1992); thus, activated PKC, via the modulation of API activity, may enhance transcription of the IL-2 and IL-2Ra genes. Both genes also exhibit binding sites for the transcription factor NF-KB which, in its inactive cytosolic form, is complexed with an inhibitor of its DNA-binding activity named I-KB; the latter has been reported to be removed from the inactive complex by a phosphorylation event, most probably mediated by PKA and/or PKC by an indirect mechanism (Shirakawa and Mizel, 1989; Gosh and Baltimore, 1990; Link et al., 1992) . Thus, PKC could be involved in transcriptional activation of the IL-2 and IL-2Ra genes in a dual way, via API and NF-cB, maybe mediated by two different PKC isoenzymes (see below).
Recent reports have pointed out the possibility that two further components of the signal transduction pathway (see Figure 1) (Morrison et al., 1991; Bruder et al., 1992 (Bruder et al., 1992) (Melloni et al., 1987) . Since levels of PKC a remained unaltered, but PKC /11/311 decreased concomitantly with the onset of differentiation, the latter isoenzyme(s) seemed to exert the key role (Melloni et al., 1989 (Table 3) . Recently, a rapid elevation of DAG levels, followed by a significant decrease, has been reported as one of the earliest events during MEL cell differentiation (Michaeli et al., 1992) .
Rather little is known of the modulation of gene expression linked to erythroid differentiation. In differentiating MEL cells, downregulation of both c-myc and c-myb gene expression has been reported (D. Eick, personal communication; Smith et al., 1990; Danish et al., 1992) which contrasts with the observation that erythroid differentiation achieved by erythropoietin in splenic erythroid cells is accompanied by an increase of c-myc RNA which seems to depend on the activation of PKC (Patel et al., 1992 (Downward et al., 1990) . Another cytoplasmic Ser/Thr to about 30%, though in parallel globin synthesis reaches a maximum (Bader and Sarre, 1986) . The dominant mechanisms of translational control involve reversible phosphorylation reactions on components like ribosomal proteins, initiation or elongation factors (Hershey, 1991) . The ribosomal protein S6 (of the 40 S subunit) as well as the initiation factors eIF-3, eIF-4E, eIF-4B and eIF-4F (the mRNA cap binding complex) have been reported to be phosphorylated in cells treated with insulin or phorbol esters (Morley and Traugh, 1990) . Whilst S6 phosphorylation is exerted by a S6 kinase which seems to be downstream of PKC in a protein kinase cascade (Susa et al., 1989 , and references cited therein), at least eIF-4F and -4E appear to be direct substrates of PKC in situ and in vitro (Morley et al., 1991; Smith et al., 1991) . Interestingly, overexpression of the cDNA encoding eIF-4E in NIH 3T3 cells lead to cellular transformation (Lazaris-Karatzas et al., 1990 ) and expression of antisense cDNA diminished the proliferation rate of HeLa cells (De Benedetti et al., 1991) .
Thus, it seems likely that translational control mechanisms involved in proliferation and differentiation events are exerted in part, directly or indirectly, by activated PKC isoenzymes.
Myeloid cells A third in situ system used for the analysis of the role of PKC in the control of differentiation involves human myeloid or promyelocytic leukaemia cell lines (HL 60, U937, K562, HEL; see Table 3 ). These cells tend to differentiate into distinct cell types depending on the inducer used: upon exposure to phorbol esters, HL 60, K562 and U937 cells show a series of monocyte/ macrophage properties, whilst HL 60 cells treated with retinoic acid or DMSO exhibit a neutrophil-like (granulocyte) phenotype (Hass et al., 1991; Okuda et al., 1991; Ways et al., 1992a,b;  and references cited in Table 3 ). In contrast, K562 cells differentiate along the erythroid lineage upon treatment with haemin (Rutherford et al., 1979; Okuda et al., 1991) . Following PMA treatment, the megakaryocyte-like HEL cells develop properties characteristic of platelets and megakaryocytes (Grabarek et al., 1992 , and references cited therein). As is the case for T cells , HL 60 cells require a sustained activation of PKC for differentiation to the macrophage phenotype (Aihara et al., 1991) . This is in agreement with the observation that high concentrations of PMA lead to differentiation of HL 60 cells whilst low doses of phorbol ester are just mitogenic , a finding which might reflect distinct roles in proliferation and differentiation events of PKC isoenzymes differing in their susceptibility towards PMA. The tremendous redistributions and changes in abundance of PKC isoenzymes observed during the differentiation processes in these cells (see above) indicate that PKC isoenzymes seem to play an important role, which will be worthwhile to elucidate.
PERSPECTIVES
An overwhelming amount of information on PKC has accumulated since its discovery in 1977. As outlined in this Review, successful work has been carried out with respect to the number of isoenzymes, their structure and biochemical properties, their expression, localization and activation within resting, proliferating and differentiating cells. In order to understand the divergent role of PKC isoenzymes in distinct signal transduction pathways, however, several aspects will require special attention in the future and intensive investigations both in vitro and by the use of appropriate cellular systems.
Physiological inducers ofa PKC response should get preference to artefactual inducers potentially exerting pleiotropic (or no) effects. Thus, in the light of the extremely different sensitivity of PKC isoenzymes to long-term PMA treatment in situ (see above), the experimental paradigm of 'PKC downregulation' should be handled with care (see also Varese et al., 1992) . Instead, a detailed analysis of the activation of distinct PKC isoenzymes in cells which respond to a specific inducer with a distinct differentiation program will provide us with much more profound insights. Recently, Szamel and Resch (1992) demonstrated that early in T cell stimulation (see above), PKC a is transiently activated whilst a prolonged activation of PKC f8 is observed after a lag phase. PKC a activation appeared to be sufficient for the expression of IL-Ra, whereas the sustained activation of PKC f was a prerequisite for the expression of Although there are potent PKC inhibitors available now (reviewed by Tamaoki and Nakano, 1990) , the development of isoenzyme-specific PKC inhibitors will be extremely useful. As described above, stable overexpression of PKC a in NIH 3T3 cells leads to a diminished growth rate. Interestingly, in these cells normal proliferative behaviour could be restored by an inhibitor for both cPKC and nPKC, but not by a cPKC-specific inhibitor (G. Martiny-Baron and C. Schachtele, personal communication). Likewise, the inhibition of the synthesis of individual PKC isoenzymes by the use of specific oligoribonucleotides as well as the intracellular use of isoenzymespecific antibodies will allow for the depletion and inactivation respectively of distinct PKC isoenzymes. Recently, Leli et al. (1992) Ohno et al. (1991) , the PKC e/y chimera of and the PKC a devoid of the regulatory domain (James and Olson, 1992). Thus, the key role of PKC isoenzymes in signal transduction and its impact on the modulation of gene expression linked to proliferative and differentiation events will be further substantiated.
